Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Vaccines Performance Helps Offset Diabetes Decline

Executive Summary

Performance of Dupixent, which just picked up a new indication, was a third quarter highlight and bodes well for future growth, but sales of the blockbuster insulin glargine Lantus are crumbling.

Advertisement

Related Content

New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value
Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel